

**COLON
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION**

VENUE: ROSSETTI ROOM, DELTA CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 27TH, 2013

TIME: 15:00 – 16:30

CHAIRS: DR. DEREK JONKER, DR. SHARLENE GILL

- 15:00 WELCOME AND INTRODUCTION **DR. D. JONKER**
- 15:00 – 15:50 APPROVED/ACTIVE TRIALS FOR DISCUSSION
- IND 210:** A RANDOMIZED PHASE II STUDY OF FOLFOX/BEVACIZUMAB +/- REOLYSIN IN METASTATIC COLORECTAL CANCER **DR. P. TANG/DR. D. JONKER**
- CO.21:** A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH EARLY STAGE COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (CHALLENGE) **DR. K. COURNEYA/DR. C. BOOTH**
- CRC.6:** (CALGB 80702): A PHASE III TRIAL OF 6 VERSUS 12 TREATMENTS OF ADJUVANT FOLFOX PLUS CELECOXIB OR PLACEBO FOR PATIENTS WITH RESECTED STAGE III COLON CANCER **DR. D. JONKER**
- IND 208:** A PHASE I TRIAL OF PANITUMUMAB + BKM120, AN ORAL PI3K INHIBITOR, IN COLORECTAL CANCER **DR. R. GOODWIN/DR. D. JONKER**
- 15:50 – 16:00 INTERGROUP TASK FORCE UPDATE **DR. D. JONKER**
- 16:00 – 16:30 CONCEPTS IN DEVELOPMENT/TRIAL PROPOSALS
- RANDOMIZED PHASE II STUDY IN BRAF MUTANT MCRC (IRINOTECAN/CETUXIMAB VS VEMURAFENIB/CETUXIMAB VS VEMURAFENIB/IRINOTECAN/CETUXIMAB)
- DR. H. KENNECKE**
- RANDOMIZED PHASE II STUDY COMPARING THE NOVEL MEK INHIBITOR, TAK-733 TO STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH KRAS MUTANT, PI3K WILD-TYPE MCRC (SWOG) **DR. D. JONKER**
- 16:30 CLOSING REMARKS